Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Efrain Reisin

Showing results (41-50 of 59) with videos related to

Pageof 6
Sort By:
Journal of the Cardiometabolic Syndrome|February 28, 2009
The role of the renin-angiotensin system in the pathophysiology, prevention, and treatment of renal impairment in patients with the cardiometabolic syndrome or its componentsMartin A Alpert, Gurushankar Govindarajan, Marc L E Del Rosario, et al.
Current Hypertension Reports|March 5, 2022
Obstructive Sleep Apnea and Hypertension: Updates to a Critical RelationshipJohn Brown, Farshid Yazdi, Mona Jodari-Karimi, et al.
The American Journal of the Medical Sciences|August 1, 2020
Evaluating Factors Contributing to Dropout in a Large Peritoneal Dialysis ProgramHayden Torres, Mihran Naljayan, Maria Frontini, et al.
Vascular Health and Risk Management|February 27, 2007
Leptin and hypertension in obesityPaco E Bravo, Stephen Morse, David M Borne, et al.
Journal of the American Society of Nephrology : JASN|April 5, 2014
Assessment and management of hypertension in patients on dialysisRajiv Agarwal, Joseph Flynn, Velvie Pogue, et al.
Life Sciences|July 28, 2009
Effects of pyrrolidine dithiocarbamate on high-fat diet-induced metabolic and renal alterations in ratsPhilip J Ebenezer, Nithya Mariappan, Carrie M Elks, et al.
The American Journal of the Medical Sciences|October 15, 2009
Effect of the HMG-CoA reductase inhibitor rosuvastatin on early chronic kidney injury in obese zucker rats fed with an atherogenic dietEfrain Reisin, Philip J Ebenezer, Jie Liao, et al.
Nephron. Experimental Nephrology|November 6, 2009
Tesaglitazar, a dual peroxisome proliferator-activated receptor agonist (PPAR alpha/gamma), improves metabolic abnormalities and reduces renal injury in obese Zucker ratsJie Liao, Zohreh Soltani, Philip Ebenezer, et al.
BMC Nephrology|December 4, 2009
End-stage renal disease in young black males in a black-white population: longitudinal analysis of the Bogalusa Heart StudyPaul Muntner, Asghar Arshad, Stephen A Morse, et al.
Archives of Internal Medicine|May 12, 2004
The prevalence of reduced glomerular filtration rate in older hypertensive patients and its association with cardiovascular disease: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack TrialMahboob Rahman, Clinton D Brown, Josef Coresh, et al.
Pageof 6

Showing results (41-50 of 59) with videos related to

Sort By:
Pageof 6
Journal of the Cardiometabolic Syndrome|February 28, 2009
The role of the renin-angiotensin system in the pathophysiology, prevention, and treatment of renal impairment in patients with the cardiometabolic syndrome or its componentsMartin A Alpert, Gurushankar Govindarajan, Marc L E Del Rosario, et al.
Current Hypertension Reports|March 5, 2022
Obstructive Sleep Apnea and Hypertension: Updates to a Critical RelationshipJohn Brown, Farshid Yazdi, Mona Jodari-Karimi, et al.
The American Journal of the Medical Sciences|August 1, 2020
Evaluating Factors Contributing to Dropout in a Large Peritoneal Dialysis ProgramHayden Torres, Mihran Naljayan, Maria Frontini, et al.
Vascular Health and Risk Management|February 27, 2007
Leptin and hypertension in obesityPaco E Bravo, Stephen Morse, David M Borne, et al.
Journal of the American Society of Nephrology : JASN|April 5, 2014
Assessment and management of hypertension in patients on dialysisRajiv Agarwal, Joseph Flynn, Velvie Pogue, et al.
Life Sciences|July 28, 2009
Effects of pyrrolidine dithiocarbamate on high-fat diet-induced metabolic and renal alterations in ratsPhilip J Ebenezer, Nithya Mariappan, Carrie M Elks, et al.
The American Journal of the Medical Sciences|October 15, 2009
Effect of the HMG-CoA reductase inhibitor rosuvastatin on early chronic kidney injury in obese zucker rats fed with an atherogenic dietEfrain Reisin, Philip J Ebenezer, Jie Liao, et al.
Nephron. Experimental Nephrology|November 6, 2009
Tesaglitazar, a dual peroxisome proliferator-activated receptor agonist (PPAR alpha/gamma), improves metabolic abnormalities and reduces renal injury in obese Zucker ratsJie Liao, Zohreh Soltani, Philip Ebenezer, et al.
BMC Nephrology|December 4, 2009
End-stage renal disease in young black males in a black-white population: longitudinal analysis of the Bogalusa Heart StudyPaul Muntner, Asghar Arshad, Stephen A Morse, et al.
Archives of Internal Medicine|May 12, 2004
The prevalence of reduced glomerular filtration rate in older hypertensive patients and its association with cardiovascular disease: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack TrialMahboob Rahman, Clinton D Brown, Josef Coresh, et al.
Pageof 6